Comparitive efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques

De Rose, Robert, Batten, C. Jane, Smith, Miranda Z., Fernandez, Caroline S., Peut, Viv, Thomson, Scott, Ramshaw, Ian A., Boyle, David B, Venturi, Vanessa, Davenport, Miles P. and Kent, Stephen J. (2007) Comparitive efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. Journal of Virology, 81 1: 292-300. doi:10.1128/JVI.01727-06

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ160840_OA.pdf Full text (open access) application/pdf 623.58KB 0

Author De Rose, Robert
Batten, C. Jane
Smith, Miranda Z.
Fernandez, Caroline S.
Peut, Viv
Thomson, Scott
Ramshaw, Ian A.
Boyle, David B
Venturi, Vanessa
Davenport, Miles P.
Kent, Stephen J.
Title Comparitive efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques
Journal name Journal of Virology   Check publisher's open access policy
ISSN 0022-538X
1098-5514
Publication date 2007-01-01
Year available 2007
Sub-type Article (original research)
DOI 10.1128/JVI.01727-06
Open Access Status File (Publisher version)
Volume 81
Issue 1
Start page 292
End page 300
Total pages 9
Place of publication Washington, DC, United States
Publisher American Society for Microbiology
Language eng
Subject 110704 Cellular Immunology
Abstract Vaccination against AIDS is hampered by great diversity between human immunodeficiency virus (HIV) strains. Heterologous B-subtype-based simian-human immunodeficiency virus (SHIV) DNA prime and poxvirus boost vaccine regimens can induce partial, T-cell-mediated, protective immunity in macaques. We analyzed a set of DNA, recombinant fowlpox viruses (FPV), and vaccinia viruses (VV) expressing subtype AE HIV type 1 (HIV-1) Tat, Rev, and Env proteins and SIV Gag/Pol in 30 pigtail macaques. SIV Gag-specific CD4 and CD8 T-cell responses were induced by sequential DNA/FPV vaccination, although lower FPV doses, VV/FPV vaccination, and DNA vaccines alone were not as consistently immunogenic. The SHIV AE DNA prime, FPV boost regimens were significantly less immunogenic than comparable B-subtype SHIV vaccination. Peak viral load was modestly (0.4 log10 copies/ml) lower among the AE subtype SHIV-immunized animals compared to controls following the virulent B subtype SHIV challenge. Protection from persistent high levels of viremia and CD4 T-cell depletion was less in AE subtype compared to B subtype SHIV-vaccinated macaques. Gag was highly immunodominant over the other AE subtype SHIV vaccine proteins after vaccination, and this immunodominance was exacerbated after challenge. Interestingly, the lower level of priming of immune responses did not blunt postchallenge Gag-specific recall responses, despite more modest protection. These studies suggest priming of T-cell immunity to prevent AIDS in humans is possible, but differences in the immunogenicity of various subtype vaccines and broad cross-subtype protection are substantial hurdles.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
Clinical Medical Virology Centre Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 41 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 42 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 15 Jan 2009, 12:49:20 EST by Paul Rollo on behalf of Library Corporate Services